JP6290187B2 - 癌の処置のためのタンパク質の部位特異的標識及び標的送達 - Google Patents

癌の処置のためのタンパク質の部位特異的標識及び標的送達 Download PDF

Info

Publication number
JP6290187B2
JP6290187B2 JP2015511804A JP2015511804A JP6290187B2 JP 6290187 B2 JP6290187 B2 JP 6290187B2 JP 2015511804 A JP2015511804 A JP 2015511804A JP 2015511804 A JP2015511804 A JP 2015511804A JP 6290187 B2 JP6290187 B2 JP 6290187B2
Authority
JP
Japan
Prior art keywords
protein
annexin
pharmaceutical composition
cancer
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015511804A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015519339A5 (enExample
JP2015519339A (ja
Inventor
クランツ，アレクサンダー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2015519339A publication Critical patent/JP2015519339A/ja
Publication of JP2015519339A5 publication Critical patent/JP2015519339A5/ja
Application granted granted Critical
Publication of JP6290187B2 publication Critical patent/JP6290187B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2015511804A 2012-05-11 2013-05-13 癌の処置のためのタンパク質の部位特異的標識及び標的送達 Expired - Fee Related JP6290187B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261688308P 2012-05-11 2012-05-11
US61/688,308 2012-05-11
US201261741984P 2012-08-01 2012-08-01
US61/741,984 2012-08-01
US201361848601P 2013-01-07 2013-01-07
US61/848,601 2013-01-07
US201361849034P 2013-01-17 2013-01-17
US61/849,034 2013-01-17
PCT/US2013/040823 WO2013170272A2 (en) 2012-05-11 2013-05-13 Site-specific labeling and targeted delivery of proteins for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2015519339A JP2015519339A (ja) 2015-07-09
JP2015519339A5 JP2015519339A5 (enExample) 2016-07-07
JP6290187B2 true JP6290187B2 (ja) 2018-03-07

Family

ID=49551481

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015511804A Expired - Fee Related JP6290187B2 (ja) 2012-05-11 2013-05-13 癌の処置のためのタンパク質の部位特異的標識及び標的送達

Country Status (5)

Country Link
US (1) US9545449B2 (enExample)
EP (1) EP2850201A4 (enExample)
JP (1) JP6290187B2 (enExample)
CA (1) CA2873112A1 (enExample)
WO (1) WO2013170272A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5149620B2 (ja) 2004-07-23 2013-02-20 エンドサイト，インコーポレイテッド ２価リンカーおよびその結合体
NZ580132A (en) 2007-03-14 2012-11-30 Endocyte Inc Binding ligand linked drug delivery conjugates of tubulysins to vitamins
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
CN104383553A (zh) 2007-06-25 2015-03-04 恩多塞特公司 含有亲水性间隔区接头的共轭物
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
JP2015536323A (ja) 2012-10-16 2015-12-21 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 非天然アミノ酸を含む薬物送達結合体および使用方法
ES2759503T3 (es) 2013-05-02 2020-05-11 Glykos Finland Oy Conjugados de una glicoproteína o un glicano con una carga útil tóxica
AU2014337555C1 (en) 2013-10-15 2021-01-28 Seagen Inc. PEGylated drug-linkers for improved Ligand-Drug Conjugate pharmacokinetics
EA201692530A1 (ru) 2014-06-13 2017-07-31 Новартис Аг Цитотоксические пептиды и их конъюгаты
CN107743494B (zh) 2015-06-02 2022-04-29 诺和诺德股份有限公司 具有极性重组延伸体的胰岛素
MX381031B (es) * 2015-08-11 2025-03-12 Coherent Biopharma | Ltd Conjugados fármaco-multiligando y usos de los mismos.
GB2542391A (en) 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture
EP3355931B1 (en) 2015-10-01 2024-06-26 Novo Nordisk A/S Protein conjugates
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
TWI852735B (zh) 2015-12-04 2024-08-11 美商思進公司 四級胺化妥布賴森(tubulysin)化合物之結合物
KR102626498B1 (ko) 2016-03-25 2024-01-19 씨젠 인크. 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
WO2018136455A1 (en) * 2017-01-17 2018-07-26 The Texas A&M University System Endolysosomal targeting conjugates for improved delivery of cargo molecules to the endolysosomal compartment of target cells
US11730822B2 (en) 2017-03-24 2023-08-22 Seagen Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
MA49339A (fr) 2017-04-05 2020-02-12 Novo Nordisk As Conjugués insuline-fc à extension oligomère
CN118027137A (zh) 2018-12-21 2024-05-14 里珍纳龙药品有限公司 微管溶素及蛋白质-微管溶素偶联物
WO2020247151A1 (en) * 2019-06-05 2020-12-10 Boston Scientific Scimed, Inc. Click chemistry capturable platinum-based antineoplastic agents
EP4366780A1 (en) * 2021-07-09 2024-05-15 Bright Peak Therapeutics AG Synthetic il-7 and il-7 immunocytokines
WO2023281482A1 (en) * 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Cd20-targeted il-2 and its uses
CN116407640B (zh) * 2023-03-03 2025-10-31 河南真实生物科技有限公司 包含阿兹夫定和化疗试剂的抗肿瘤药物组合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066490A (en) 1988-06-01 1991-11-19 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Protein crosslinking reagents cleavable within acidified intracellular vesicles
EP1001968B1 (en) 1997-06-13 2004-12-22 Gryphon Therapeutics, Inc. Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution
US6017876A (en) 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
US5900404A (en) 1997-08-15 1999-05-04 Amgen Inc. Chemical modification of proteins to improve biocompatibility and bioactivity
US6787154B2 (en) 1998-10-20 2004-09-07 Salvatore Albani Artificial antigen presenting cells
WO2002042427A2 (en) 2000-10-25 2002-05-30 Surromed, Inc. Mass tags for quantitative analysis
WO2002087497A2 (en) * 2001-04-26 2002-11-07 Board Of Regents, The University Of Texas System Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
US20030215877A1 (en) 2002-04-04 2003-11-20 California Institute Of Technology Directed protein docking algorithm
GB0209896D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
EP1534269B1 (en) 2002-07-19 2013-10-30 The General Hospital Corporation Oxime conjugates and methods for their formation and use
US20110002978A1 (en) * 2003-06-17 2011-01-06 Harrison Roger G Enzyme prodrug cancer therapy selectively targeted to tumor cells or tumor vasculature and methods of production and use thereof
US20070123465A1 (en) 2004-06-18 2007-05-31 Ipf Pharmaceuticals Gmbh Oligomeric peptides and their use for the treatment of hiv infections
WO2007112362A2 (en) 2006-03-24 2007-10-04 The Regents Of The University Of California Construction of a multivalent scfv through alkyne-azide 1,3-dipolar cycloaddition
WO2009158668A1 (en) * 2008-06-26 2009-12-30 Prolynx Llc Prodrugs and drug-macromolecule conjugates having controlled drug release rates
EP2350112A4 (en) * 2008-10-03 2013-01-16 Advanced Proteome Therapeutics Inc Site specific N-termin protein modifications and conjugate formation
CA2764029C (en) 2009-06-03 2019-10-29 Mosamedix B.V. Method for enhancing phagocytosis of phosphatidylserine-exposing cells
WO2011103409A1 (en) * 2010-02-18 2011-08-25 Advanced Proteome Therapeutics Inc. Site-specific modification of proteins through chemical modification enabling protein conjugates, protein dimer formation, and stapled peptides
WO2011140392A1 (en) * 2010-05-05 2011-11-10 Prolynx Llc Controlled drug release from solid supports
WO2011153250A2 (en) * 2010-06-01 2011-12-08 Advanced Proteome Therapeutics Inc. Crosslinking of proteins and other entities via conjugates of alpha-haloacetophenones, benzyl halides, quinones, and their derivatives

Also Published As

Publication number Publication date
WO2013170272A2 (en) 2013-11-14
EP2850201A2 (en) 2015-03-25
CA2873112A1 (en) 2013-11-14
US20150202314A1 (en) 2015-07-23
US9545449B2 (en) 2017-01-17
WO2013170272A3 (en) 2014-02-27
EP2850201A4 (en) 2016-08-31
JP2015519339A (ja) 2015-07-09

Similar Documents

Publication Publication Date Title
US9545449B2 (en) Site-specific labeling and targeted delivery of proteins for the treatment of cancer
Rahimizadeh et al. Albumin: an emerging opportunity in drug delivery
JP7490735B2 (ja) ジスルフィド含有細胞膜透過ペプチド並びにその製造方法及び使用方法
US10894813B2 (en) Methods of using therapeutic p53 peptides
CN105934257B (zh) 用于含氮和羟基的药物的生物可逆引入基团
ES2349743T3 (es) Derivados de la il-21.
JP7425606B2 (ja) 四級化ニコチンアミドアデニンジヌクレオチドサルベージ経路阻害剤コンジュゲート
CN117567535A (zh) 生物正交组合物
WO2007076371A2 (en) Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
JP2011184442A (ja) Ｉｌ−２１の誘導体
CN104666246A (zh) 口服生物利用的基于脂质的结构
CN102245636A (zh) 用于药物递送的依托泊苷和多柔比星结合物
TW202500573A (zh) 細胞穿透肽序列
JP2019196358A (ja) 血清半減期を延長するための、調節可能リンカーを介した薬学的活性剤とトランスサイレチンリガンドのコンジュゲーション
US9770515B2 (en) Crosslinking of proteins and other entities via conjugates of α-haloacetophenones, benzyl halides, quinones, and their derivatives
Lim Site-specific bioconjugation and self-assembly technologies for multi-functional biologics: on the road to the clinic
WO2023077129A1 (en) Tetrazine conjugates for in vivo targeted delivery of a payload
JP2024512775A (ja) 抗ｈｅｒ２抗体薬物コンジュゲート及びその使用
WO2023077126A1 (en) Trans-cyclooctene conjugates
JP2021521270A (ja) 治療剤の制御放出用組成物
JP2007533298A (ja) Ｉｌ−２１の誘導体
WO2017212494A1 (en) Long-acting oxyntomodulin formulation and methods of producing and administering same
WO2018183232A2 (en) Peptides and methods for targeted delivery to tumors
EP4704904A1 (en) Tetrazine-based targeting agents for in vivo delivery of a payload
JP2025532958A (ja) ＥｐｈＡ２結合保留ペプチド及びそれを含む組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160511

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180207

R150 Certificate of patent or registration of utility model

Ref document number: 6290187

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees